We hypothesized that the induction of tumor inflammation with the treatment of AS1411-SMG1-AsiC creates the optimal conditions to sensitize the tumor to the action of ICB agents such as anti-CTLA-4/PD-1 antibodies. This evidence concerns the gene CTLA4 and neoplasm.